<DOC>
	<DOC>NCT00239915</DOC>
	<brief_summary>This is a research study of the investigational drug, Pagoclone, in the treatment of persistent developmental stuttering (PDS), which includes frequent repetitions or prolongations of sounds or syllables or words, or frequent hesitations or pauses that disrupt the flow of speech. Pagoclone is an investigational drug, so it is not approved by the United States Food and Drug Administration.</brief_summary>
	<brief_title>Safety and Efficacy Study of the Investigational Drug Pagoclone, in the Treatment of Persistent Developmental Stuttering (PDS)</brief_title>
	<detailed_description />
	<mesh_term>Stuttering</mesh_term>
	<criteria>PDS defined as DSMIVTR criteria Symptoms starting before age 8 Total overall score of 1836 on the SSI3 English speaking, with an 8th grade education Able to understand and cooperate with study requirements with assistance Not pregnant or breastfeeding Able to provide consent No diagnoses of other CNS/Mental health disorders in the last 6 months No use of psychotropic medication or other medication for stuttering within 4 weeks prior to screening No use of nonmedicinal stuttering treatments for 5 months prior to the study No use of illicit drugs or opiates of any kind</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>